To include your compound in the COVID-19 Resource Center, submit it here.
Effector began an open-label, dose-escalation, dose-expansion, U.S. Phase I/II trial to evaluate oral
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury